AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32026432
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (observation with serial MRI scans)
Trial: 32991492
Drug: Maternal use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal use of beta-blockers during the first trimester of pregnancy
Trial: 32389105
Drug: Liberal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal blood glucose control (target 10.0-14.0 mmol/L)
Trial: 32389105
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (target 6.0-10.0 mmol/L)
Trial: 35173379
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) training for 5 weeks, twice a week, 30 min sessions
Trial: 34563227
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinician and patient-directed nudges
Trial: 34953526
Drug: Ad5-nCoV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-nCoV vaccine (0.5 mL dose of 5 × 10^10 viral particle/mL)
Trial: 36888640
Drug: Ad5-nCoV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-nCoV vaccine
Trial: 36383249
Drug: Caffeine containing
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine containing multi-ingredient pre-workout supplement (SUPP)
Trial: 34036721
Drug: Standard-of-care therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapies (radiotherapy and temozolomide chemotherapy)
Trial: 34339267
Drug: SPR206 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR206 (10 mg to 400 mg single doses; 25 mg to 150 mg every 8 hours for 7 days; 100 mg every 8 hours for 14 days)
Trial: 34339267
Drug: SPR206 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR206 (100 mg every 8 hours for 14 days)
Trial: 34339267
Drug: SPR206 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR206 (various doses)
Trial: 34706189
Drug: Sotrovimab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab (500 mg single infusion)
Trial: 35133556
Drug: PCIT-ED treatment
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIT-ED treatment (n=94)
Trial: 34743631
Drug: Audiovisual lecture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audiovisual lecture only (Group L)
Trial: 37086245
Drug: Istaroxime (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime (0.5 mg/kg/min)
Trial: 37086245
Drug: Istaroxime (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime (1.0 mg/kg/min)
Trial: 33235342
Drug: Chronic medication
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic medication with anticoagulants or antihypertensives
Trial: 33653271
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (COT) - FiO2 of 1.0, 12 L/min
Trial: 34330770
Drug: Intermediate-acting insulin
RxNorm normalized name: Intermediate-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-acting insulin isophane for postoperative afternoon glucose ≥140 mg/dl
Trial: 34330770
Drug: Short-acting insulin
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting insulin for fasting glucose ≥200 mg/dl (control)
Trial: 32337566
Drug: Weekly Osteopathic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly Osteopathic Manipulative Treatment (OMT) for 12 consecutive weeks
Trial: 32450106
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (5 × 10^10 viral particles)
Trial: 32450106
Drug: Middle dose
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle dose (1 × 10^11 viral particles)
Trial: 32450106
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (1.5 × 10^11 viral particles)
Trial: 34419006
Drug: Far infrared
RxNorm normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far infrared therapy (FIR) applied to the skin above the AVF three times a week for 1 year
Trial: 34419006
Drug: Far infrared
RxNorm normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far infrared therapy (FIR)
Trial: 32788865
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (RSV) therapy
Trial: 32741946
Drug: Lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide plus low-dose dexamethasone therapy
Trial: 36014810
Drug: Multi-strain probiotic
RxNorm normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strain probiotic formulation (LabinicTM)
Trial: 38082431
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavioral therapy (CBT)
Trial: 34753814
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg of salbutamol
Trial: 34753814
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 mL of nebulized sodium chloride)
Trial: 35077215
Drug: Combined ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ultrasound and electrostimulation (CUSECS) with standard wound care treatment twice a week for 8 weeks
Trial: 35077215
Drug: Standard wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard wound care treatment once a week for 8 weeks
Trial: 35077215
Drug: Standard wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard wound care treatment
Trial: 36112378
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous antibiotic (cloxacillin 2 g per dose)
Trial: 36112378
Drug: Multiple-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose intravenous antibiotic (cloxacillin 2 g per dose over 24 hours)
Trial: 36112378
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous antibiotic
Trial: 36112378
Drug: Multiple-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose intravenous antibiotic
Trial: 33274674
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral feeding
Trial: 34959801
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day DHA
Trial: 34959801
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day DHA
Trial: 35259681
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) control
Trial: 34570315
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) adherence intervention
Trial: 34570315
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) adherence during lockdown
Trial: 35654318
Drug: Losartan (AT1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (AT1R antagonist), single dose
Trial: 33784411
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220µg)
Trial: 34255874
Drug: BiV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiV therapy
Trial: 34491513
Drug: MD (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD (220 mg/m2)
Trial: 34491513
Drug: LD (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD (180 mg/m2)
Trial: 34491513
Drug: SD (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD (260 mg/m2)
Trial: 34798892
Drug: Cranberry supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry supplementation (144 mg capsule)
Trial: 32250330
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (T) therapy
Trial: 35728921
Drug: Azithromycin 250-mg
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250-mg tablet manufactured at Pfizer Dalian (China)
Trial: 35728921
Drug: Azithromycin 250-mg
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250-mg tablet manufactured at Pfizer Barceloneta (United States)
Trial: 32903168
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon angioplasty
Trial: 32157686
Drug: Group education
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group education and medical nutrition therapy (MNT) sessions provided within 1-2 weeks of GDM diagnosis.
Trial: 35260388
Drug: Biomarker-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided therapy withdrawal (based on S100A12 and hsCRP levels)
Trial: 35260388
Drug: Continuing therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuing therapy due to elevated S100A12/hsCRP levels
Trial: 35260388
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (BiKeR registry, therapy withdrawal without biomarker-based stratification)
Trial: 35260388
Drug: Biomarker-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided therapy withdrawal
Trial: 35921872
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg in a 24/4‐day regimen
Trial: 35320161
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus over 10 min, followed by 1.5 mg/kg/h infusion for 24 hours)
Trial: 35320161
Drug: Saline (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo administered at the same rate as lidocaine)
Trial: 35787943
Drug: Tegoprazan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (50 mg tablet, once daily) and Naproxen (500 mg tablet, twice daily)
Trial: 35787943
Drug: Tegoprazan and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan and Aceclofenac (100 mg tablet, twice daily)
Trial: 35787943
Drug: Tegoprazan and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan and Celecoxib (200 mg capsule, twice daily)
Trial: 34187840
Drug: Fast fluid
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast fluid infusion (0.90% saline)
Trial: 34187840
Drug: Fast fluid
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast fluid infusion
Trial: 34187840
Drug: Slow fluid
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow fluid infusion
Trial: 36012011
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (ST) twice a week at 75% intensity of one‐repetition maximum for 10 weeks during winter
Trial: 35645037
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg cefuroxime sodium plus 500 mg intravenous azithromycin (experimental group)
Trial: 35645037
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg cefuroxime sodium plus placebo (placebo group)
Trial: 33259240
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A (BTX‐A) injection
Trial: 35439645
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no estrogen therapy)
Trial: 33525419
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic Weissella cibaria CMU
Trial: 34684621
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g MSM daily for 16 weeks
Trial: 36321379
Drug: nCT (chemotherapy)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCT (chemotherapy)
Trial: 32908007
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Roseomonas mucosa
Trial: 35987213
Drug: vehicle glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle glucose or no supplement
Trial: 33872583
Drug: Choline bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline bitartrate supplements (n = 20)
Trial: 33872583
Drug: Hardboiled eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hardboiled eggs + choline bitartrate supplements (n = 16)
Trial: 33872583
Drug: Egg whites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg whites + choline bitartrate supplements (n = 18)
Trial: 33872583
Drug: Phosphatidylcholine supplements
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine supplements (n = 10)
Trial: 32810220
Drug: Ofatumumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (1000 mg)
Trial: 36431201
Drug: Standardized punicalagin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized punicalagin enriched oral pomegranate extract (Pomella®) daily for four weeks
Trial: 34053748
Drug: Oral regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral regimen causing moderate nausea
Trial: 34053748
Drug: Monthly IV
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly IV regimen causing mild memory problems
Trial: 34053748
Drug: Weekly IV
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly IV regimen causing mild memory and mild neuropathy
Trial: 32967068
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D (ergocalciferol) at 40,000 IU per week
Trial: 32405570
Drug: High NO3−
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NO3− (140 ml of beetroot juice (BJ) per day, 800 mg of NO3−/day)
Trial: 32405570
Drug: Moderate NO3−
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate NO3− (70 ml of BJ per day, 400 mg of NO3−/day)
Trial: 32405570
Drug: Low NO3−
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NO3− (70 ml on alternate days, 400 mg of NO3−)
Trial: 32405570
Drug: NO3− depleted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3− depleted (70 ml on alternate days, 0.001 mg of NO3)
Trial: 33639543
Drug: Heart-focused breathing
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart-focused breathing protocol (10 minutes daily for 2 weeks)
Trial: 32375661
Drug: Digital reminiscence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital reminiscence therapy (digital RT), 8 sessions over 4 weeks.
Trial: 32375661
Drug: Conventional reminiscence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional reminiscence therapy (storytelling, control group), 8 sessions over 4 weeks.
Trial: 32815384
Drug: Standard physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physiotherapy treatment
Trial: 34183510
Drug: Non-antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antibiotic treatment (anti-inflammatory and symptomatic treatment)
Trial: 34183510
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (875/125 mg/8 h amoxicillin/clavulanic acid)
Trial: 34102933
Drug: Daily screen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily screen time
Trial: 33316557
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic treatment
Trial: 32736597
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg twice daily on day 1, followed by 200 mg twice daily on days 8, 15, and 22 for Group 1; 400 mg twice daily on day 1 followed by 200 mg twice daily for 5-7 days for Group 2)
Trial: 38174567
Drug: Dual-antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet therapy (DAPT)
Trial: 35960075
Drug: astragalus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: astragalus injection with chemotherapy regimen containing anthracycline epirubicin
Trial: 35960075
Drug: chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy regimen containing anthracycline epirubicin
Trial: 39206189
Drug: AS03-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted vaccine
Trial: 35149205
Drug: AYUSH‐64 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AYUSH‐64 (two tablets of 500 mg each, three times a day for 30 days)
Trial: 36164014
Drug: Momelotinib (MMB)
RxNorm normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib (MMB) 200 mg QD for 24 weeks
Trial: 36164014
Drug: Danazol (DAN)
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol (DAN) 600 mg QD for 24 weeks
Trial: 33611104
Drug: Lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 24 mg daily (n = 261)
Trial: 33459247
Drug: Methyl Jasmonate
RxNorm normalized name: jasmone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl Jasmonate (MJ) treatment at 30 mM
Trial: 33459247
Drug: Methyl Jasmonate
RxNorm normalized name: jasmone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl Jasmonate (MJ) treatment at 60 mM
Trial: 33459247
Drug: Methyl Jasmonate
RxNorm normalized name: jasmone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl Jasmonate (MJ) treatment at 100 mM
Trial: 34606114
Drug: Two-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose group (tetravalent measles-mumps-rubella-varicella vaccine)
Trial: 34606114
Drug: One-dose group
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose group (monovalent varicella vaccine)
Trial: 33872815
Drug: Follicular flushing
RxNorm normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Follicular flushing (FF) using a 17-G double lumen needle
Trial: 33872815
Drug: Direct follicular
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct follicular aspiration using a 17-G single lumen needle
Trial: 36346534
Drug: Safinamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide (50 mg once daily, increased to 100 mg once daily at day 15)
Trial: 32003644
Drug: Trigonal Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigonal Botulinum toxin‐A (BTX‐A) injections (240 U into the detrusor plus 60 U into the trigone)
Trial: 32003644
Drug: Nontrigonal Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontrigonal Botulinum toxin‐A (BTX‐A) injections (300 U into the detrusor sparing the trigone)
Trial: 32293523
Drug: Benznidazole (BNZ)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BNZ) 150 mg/day for 60 days
Trial: 32293523
Drug: Benznidazole (BNZ)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BNZ) 400 mg/day for 15 days